Moderna Inc (MRNA)
Gross profit margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Gross profit | US$ in thousands | 1,772,000 | 2,155,000 | 13,847,000 | 15,119,000 | 266,557 |
| Revenue | US$ in thousands | 3,236,000 | 6,848,000 | 19,263,000 | 17,736,000 | 274,490 |
| Gross profit margin | 54.76% | 31.47% | 71.88% | 85.24% | 97.11% |
December 31, 2024 calculation
Gross profit margin = Gross profit ÷ Revenue
= $1,772,000K ÷ $3,236,000K
= 54.76%
Based on the data provided, Moderna Inc's gross profit margin has exhibited fluctuations over the five-year period specified. The trend shows a gradual decline in the margin percentage from 97.11% as of December 31, 2020, to 54.76% as of December 31, 2024. The sharp drop in the gross profit margin from 85.24% in 2021 to 71.88% in 2022 is notable, indicating potential challenges in managing production costs or pricing strategies during that period. Subsequently, the margin further decreases significantly by the end of 2023 before showing a partial recovery at the end of 2024.
The lower gross profit margins in recent years may be indicative of various factors such as increasing production costs, changes in product pricing, competitive pressures, or fluctuations in revenue streams. It suggests a need for Moderna Inc to assess and address the underlying reasons for the decline to maintain profitability and sustainability in the long term. Further analysis of cost structures and revenue generation strategies may be required to optimize the company's gross profit margin and enhance overall financial performance.
Peer comparison
Dec 31, 2024